PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it will present four posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22 at the San Diego Convention Center in San Diego, California. The presentations will include one ...

Clinical Efficacy and Research - BriaCell reported a median overall survival of 13.4 months for metastatic breast cancer patients treated with Bria-IMT™, compared to 6.7-9.8 months for similar patients in literature[91]. - The ongoing pivotal Phase 3 study of Bria-IMT™ has over 230 patients screened and more than 160 patients enrolled, with topline data expected in the first half of 2026[99]. - BriaCell's Phase 2 study showed that 9 out of 25 patients treated since 2022 survived over 18-47 months, significantly exceeding benchmarks for standard therapies[104]. - The Phase 2 study of Bria-IMT™ demonstrated a median overall survival of 15.6 months, with 52% of patients surviving one year and 32% surviving two years[107]. - BriaCell's Bria-OTS™ platform is being developed for personalized off-the-shelf immunotherapies across multiple cancer types, with positive feedback from the FDA[93]. - The company highlighted positive Phase 2 data at the San Antonio Breast Cancer Symposium, emphasizing the clinical benefit and safety of the Bria-IMT regimen[103]. - BriaCell reported a sustained complete resolution of lung metastasis in a patient after 11 months of treatment with Bria-OTS, confirming the efficacy of the therapy[125]. - BriaCell's collaboration with Memorial Sloan Kettering Cancer Center aims to accelerate clinical development of Bria-OTS+ across various cancer indications[97]. - No toxicity-related discontinuations were reported in the ongoing Phase 3 study, indicating a favorable safety profile for the Bria-IMT regimen[103]. Financial Performance - For the three months ended January 31, 2026, total operating expenses were $7,531,266, compared to $7,169,443 for the same period in 2025, reflecting an increase of approximately 5.1%[138]. - Research and development expenses for the three-month period ended January 31, 2026, were $6,053,689, up from $5,684,777 in 2025, representing an increase of about 6.5%[138]. - Clinical trial expenses for the three months ended January 31, 2026, were $5,008,171, compared to $3,923,559 during the same period in 2025, indicating a year-over-year increase of approximately 27.7%[142]. - The Bria-IMT™ Pivotal Phase 3 Study costs were $3,874,242 for the three months ended January 31, 2026, compared to $3,642,650 in 2025, reflecting an increase of about 6.4%[143]. - The Bria-OTS™ Phase 1/2a expenses were $936,726 for the three months ended January 31, 2026, compared to $65,608 in 2025, showing a significant increase of approximately 1,326%[145]. - The net loss for the period attributable to BriaCell was $7,221,820 for the three months ended January 31, 2026, compared to $6,291,420 in 2025, representing an increase of about 14.8%[139]. - The Company reported a net loss of $7,296,893 for the three-month period ended January 31, 2026, compared to a loss of $6,337,828 for the same period in 2025, driven by increased operating expenses[148]. - For the six-month period ended January 31, 2026, total operating expenses were $15,854,209, up from $12,322,275 in 2025, with research and development expenses rising to $12,737,332 from $9,350,118[149]. - Clinical trial expenses for the six months ended January 31, 2026, were $9,952,363, compared to $6,631,649 in 2025, reflecting significant investment in clinical programs[152]. Capital and Funding - BriaCell received a US$2.0 million Small Business Innovation Research grant from the U.S. National Cancer Institute to support the Bria-PROS+™ program in prostate cancer[98]. - The Company intends to raise additional capital through debt or equity financings to support its business plan objectives[163]. - Cash gained in financing activities for the period ended January 31, 2026, was $27,874,441, compared to $17,176,863 for the same period in 2025[165]. Assets and Liabilities - As of January 31, 2026, the Company had total assets of $33,594,454, up from $21,649,706 as of July 31, 2025, and a positive working capital of $28,993,334[161]. - The accumulated deficit as of January 31, 2026, was $127,174,949, an increase from $111,755,564 as of July 31, 2025[161]. - The Company’s net cash used in operating activities during the period ended January 31, 2026, was $15,672,094, compared to $12,875,298 for the same period in 2025[164]. Shareholder Information - The weighted average number of shares used in computing net basic and diluted earnings per share of common stock was 2,802,337 for the three months ended January 31, 2026, compared to 269,957 in 2025, indicating a substantial increase in share count[139]. - BriaPro has agreed to purchase BriaCell's exclusive license to develop and commercialize Soluble CD80, with BriaCell receiving approximately C$1.18M in common shares as part of the transaction[129][133]. General and Administrative Expenses - General and administrative expenses for the six-month period ended January 31, 2026, amounted to $3,116,877, compared to $2,972,157 in 2025, primarily due to higher wages and regulatory fees[156]. Valuation and Financial Instruments - Cash and cash equivalents are valued using quoted market prices in active markets[179]. - The fair value of the warrant liability is determined based on the nature of the warrant[179]. - For publicly traded warrants, the quoted market price is used[179]. - For all other warrants, the Black-Scholes pricing model is applied[179].

Core Insights - BriaCell Therapeutics Corp. announced that four abstracts have been accepted for poster presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 17th – 22nd in San Diego, CA [1][2] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [4] Research Highlights - The accepted abstracts will showcase research related to BriaCell's cellular immunotherapy platform, including the ongoing pivotal Phase 3 study of Bria-IMTᵀᴹ in combination with an immune checkpoint inhibitor (ClinicalTrials.gov identifier: NCT06072612) [2] - Additionally, the research will support Bria-OTS+ᵀᴹ, which is BriaCell's next-generation personalized off-the-shelf immunotherapy program [2] Presentation Details - Poster titles and presentation details will be available on March 17, 2026, at 4:30 PM ET, coinciding with the publication of the abstracts in the online Proceedings of AACR [3]

Core Viewpoint - BriaCell Therapeutics Corp. has successfully closed a public offering of 5,366,726 units, raising approximately US$30 million to support its business objectives and working capital needs [1][2]. Group 1: Offering Details - Each unit in the offering consists of one common share (or one pre-funded warrant) and one warrant, sold at a price of US$5.59 per unit [1]. - The warrants are immediately exercisable at an exercise price of US$6.93 per share and will expire five years from the date of issuance [1]. - The warrants have been approved for listing on the Nasdaq Capital Market under the symbol "BCTXL" and began trading on January 14, 2026 [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital requirements, general corporate purposes, and advancing the company's business objectives [2]. Group 3: Regulatory Information - A registration statement related to the securities was filed with the SEC on December 23, 2025, and became effective on January 13, 2026 [3]. - The offering was conducted in accordance with the exemption set forth in Section 602.1 of the TSX Company Manual [2]. Group 4: Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [5].

Group 1 - U.S. stock futures are lower, with Dow futures down approximately 100 points [1] - Glaukos Corp reported preliminary FY25 sales of $507 million, leading to a 12.1% drop in shares to $96.97 in pre-market trading [1] Group 2 - Briacell Therapeutics Corp experienced a significant decline of 53.1% to $5.12 after announcing a $30 million public offering [2] - Trip.com Group Ltd shares fell 9.3% to $68.55 amid an investigation by China's SAMR for potential anti-monopoly violations [2] - Pearson PLC shares decreased by 7.2% to $13.36 following a trading update for 2025 [2] - Olema Pharmaceuticals Inc shares declined 5.5% to $26.37 after a previous drop of 3% [2] - Fresenius Medical Care AG shares fell 4.8% to $21.79 [2] - Ambitions Enterprise Management Co LLC shares dropped 4.3% to $11.81 after a significant increase of 134% the previous day [2] - NovaBay Pharmaceuticals Inc shares decreased by 3.8% to $12.55 following a 3% drop on Tuesday [2] - SmartRent Inc shares fell 2.3% to $1.74 in pre-market trading [2]

Group 1 - BriaCell Therapeutics Corp. announced a public offering of 5.367 million units priced at $5.59 per unit, aiming for gross proceeds of approximately $30 million [1] - Each unit consists of one common share and one warrant, with the warrant exercisable at $6.93 per share and expiring five years from issuance [1] - Following the announcement, the stock price dropped 54.12% to $5.01 [2] Group 2 - The warrants have been approved for listing on the Nasdaq Capital Market under the symbol "BCTXL," expected to begin trading on January 14, 2026 [2] - The offering is anticipated to close on January 15, 2026 [2] - The company plans to use the net proceeds for working capital and general corporate purposes [3] Group 3 - BriaCell recently reported a sustained complete resolution of lung metastasis in a breast cancer patient treated with its Bria-OTS personalized immunotherapy, boosting stock prices to $12.10 [3] - Over 11 months, the treatment response was confirmed without treatment-limiting toxicities, enhancing confidence in the Bria-OTS platform [4] - The stock traded between $3.00 and $98.20 over the past year, closing at $10.92, up 43.12% prior to the offering announcement [4]

Group 1: Company Performance - Gelteq Ltd (NASDAQ:GELS) shares rose sharply by 50.1% to $1.25 in pre-market trading after reporting positive preclinical results for its cannabinoid oral gel delivery platform [1][2] - The proprietary oral gel platform achieved a greater than 22% increase in the bioavailability of cannabidiol compared to an existing FDA-approved oil-based product [1] Group 2: Other Notable Stock Movements - Inspire Veterinary Partners Inc (NASDAQ:IVP) gained 141.3% to $0.056 after filing a Certificate of Amendment to increase its authorized Class A common stock from 100 million to 700 million shares [5] - Oriental Culture Holding Ltd (NASDAQ:OCG) rose 40.8% to $0.016 following the board's approval of a special cash dividend of 5 cents per share [5] - XCF Global Inc (NASDAQ:SAFX) gained 30.2% to $0.22 after announcing expansion financing plans [5] - AiRWA Inc (NASDAQ:YYAI) rose 15.8% to $1.46 after a director purchased 1.109 million shares at an average price of $1.35 per share [5] - Autolus Therapeutics PLC (NASDAQ:AUTL) gained 7.3% to $1.47 after announcing preliminary fourth-quarter and FY25 revenue results [5] Group 3: Declining Stocks - Briacell Therapeutics Corp (NASDAQ:BCTX) fell 53.1% to $5.12 after announcing the pricing of a $30 million public offering [5] - Moolec Science SA (NASDAQ:MLEC) fell 19.8% to $3.94 after a previous jump of 19% [5] - Hub Cyber Security Ltd (NASDAQ:HUBC) fell 19.1% to $0.43 after gaining 56% on the previous day [5] - Trip.com Group Ltd (NASDAQ:TCOM) dipped 9.3% to $68.55 amid an investigation by China's SAMR for potential anti-monopoly violations [5]

Core Viewpoint - BriaCell Therapeutics Corp. has announced a public offering of 5,366,726 units at a price of $5.59 per unit, aiming to raise approximately $30 million before expenses [1][2]. Group 1: Offering Details - Each unit consists of one common share (or a pre-funded warrant) and one warrant, with the warrants approved for listing on the Nasdaq Capital Market under the symbol "BCTXL" [1]. - The warrants are immediately exercisable at an exercise price of $6.93 per share and will expire five years from issuance [1]. - The offering is expected to close on January 15, 2026, subject to customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund working capital requirements, general corporate purposes, and to advance the company's business objectives [3]. Group 3: Regulatory Information - A registration statement related to the securities was filed with the SEC on December 23, 2025, and became effective on January 13, 2026 [4]. - The offering is being made only by means of a prospectus, with copies available from ThinkEquity and on the SEC's website [4]. Group 4: Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care [6].

Core Viewpoint - BriaCell Therapeutics Corp. has announced a public offering of 5,366,726 units at a price of $5.59 per unit, aiming to raise approximately $30 million before expenses [1][2]. Group 1: Offering Details - Each unit consists of one common share (or a pre-funded warrant) and one warrant, with the warrants approved for listing on the Nasdaq Capital Market under the symbol "BCTXL" [1]. - The warrants are immediately exercisable at an exercise price of $6.93 per share and will expire five years from issuance [1]. - The offering is expected to close on January 15, 2026, subject to customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for working capital requirements, general corporate purposes, and advancing the company's business objectives [3]. Group 3: Regulatory Information - A registration statement related to the securities was filed with the SEC on December 23, 2025, and became effective on January 13, 2026 [4]. - The offering is being made only by means of a prospectus, with copies available from ThinkEquity [4]. Group 4: Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care [6].

Core Insights - Several biotechnology and pharmaceutical companies experienced significant stock price increases in after-hours trading, driven by corporate updates, clinical milestones, and acquisition speculation [1] Company Updates - China SXT Pharmaceuticals, Inc. (SXTC) saw a 13.6% increase to $1.42, following the announcement of its Strategic Artificial Intelligence Insights Initiative aimed at integrating AI-driven analytics into product planning and market intelligence [2] - Revolution Medicines, Inc. (RVMD) surged 15.1% to $123.65 after reports of Merck's acquisition talks and the FDA granting Breakthrough Therapy Designation to its drug zoldonrasib for treating specific lung cancer patients [3] - KalVista Pharmaceuticals, Inc. (KALV) advanced 14.0% to $18.04 after reporting preliminary unaudited global net product revenue results for Q4 and the full year ended December 31, 2025, along with other operational indicators [4] - Zentalis Pharmaceuticals, Inc. (ZNTL) rose 8.1% to $3.07, likely due to investor reactions to a previous corporate update outlining key milestones for its drug azenosertib [5] - BriaCell Therapeutics Corp. (BCTX) gained 7.3% to $7.81 without new announcements, indicating momentum-driven trading [6] - Sagimet Biosciences Inc. (SGMT) increased 7.7% to $6.00 after announcing plans to present clinical trial results at an upcoming conference, highlighting anti-fibrotic effects observed in patients [7]